Prostate CA Clinical Trials

1,211 recruitingLast updated: June 17, 2026

There are 1,211 actively recruiting prostate ca clinical trials across 68 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include New York, New York, United States, Los Angeles, California, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Prostate CA Trials at a Glance

1,211 actively recruiting trials for prostate ca are listed on ClinicalTrialsFinder across 6 cities in 68 countries. The largest study group is Not Applicable with 349 trials, with the heaviest enrollment activity in New York, Los Angeles, and Houston. Lead sponsors running prostate ca studies include National Cancer Institute (NCI), Mayo Clinic, and Novartis Pharmaceuticals.

Treatments under study

About Prostate CA Clinical Trials

Looking for clinical trials for Prostate CA? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Prostate CA trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Prostate CA clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 1,211 trials

Recruiting
Phase 3

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Stage IVB Prostate Cancer AJCC v8Metastatic Prostate AdenocarcinomaMetastatic Castration-Resistant Prostate Carcinoma
Alliance for Clinical Trials in Oncology1,524 enrolled98 locationsNCT07200830
Recruiting
Phase 1Phase 2

First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer

Metastatic Prostate Cancer
AstraZeneca42 enrolled8 locationsNCT07529717
Recruiting
Phase 1Phase 2

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals123 enrolled19 locationsNCT07226986
Recruiting
Not Applicable

Alpha Radiation Emitters Device (DaRT) for the Treatment of Non-Metastatic Locally Recurrent Prostate Cancer.

Non-metastatic Prostate CancerLocally Recurrent Prostate Cancer
Alpha Tau Medical LTD.10 enrolled1 locationNCT06202248
Recruiting
Phase 3

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Metastatic Castration-resistant Prostate Cancer
Pfizer900 enrolled240 locationsNCT06629779
Recruiting
Phase 3

Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer

Prostate Cancer
Memorial Sloan Kettering Cancer Center224 enrolled8 locationsNCT07548164
Recruiting
Phase 1

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Metastatic Castration-resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer ( SCLC )Follicular Lymphoma ( FL)
Pfizer453 enrolled83 locationsNCT03460977
Recruiting
Phase 3

Radiotherapy After Prostatectomy for Node Positive Prostate Cancer

Androgen Deprivation TherapyProstate Cancer (Post Prostatectomy)Prostate Cancer Non-Metastatic+2 more
Sun Yat-sen University372 enrolled13 locationsNCT07477626
Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled578 locationsNCT03866382
Recruiting

Precision-Based Genomics in Prostate Cancer

Prostate Cancer
National Cancer Institute (NCI)2,000 enrolled11 locationsNCT04706663
Recruiting

Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue

Prostate Cancer
National Cancer Institute (NCI)3,000 enrolled1 locationNCT02594202
Recruiting

Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy

Prostate CancerProstatic Neoplasms
National Cancer Institute (NCI)300 enrolled1 locationNCT01834001
Recruiting
Phase 2

Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation

Prostate Cancer
University of Chicago57 enrolled1 locationNCT05790213
Recruiting
Phase 4

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Non-metastatic Castration-resistant Prostate Cancer
Bayer50 enrolled25 locationsNCT05348876
Recruiting
Phase 2

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

Prostate CancerHigh-risk Prostate Cancer
Icahn School of Medicine at Mount Sinai40 enrolled1 locationNCT07027124
Recruiting
Phase 2

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

Prostate CancerProstate AdenocarcinomaHormone Sensitive Prostate Cancer
University of Miami34 enrolled1 locationNCT06392295
Recruiting

An Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cancer in Australia

Metastatic Hormonesensitive Prostate Cancer (mHSPC)
Bayer1,000 enrolled1 locationNCT07223372
Recruiting
Phase 3

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Prostate CancerProstatic Neoplasms
Merck Sharp & Dohme LLC1,440 enrolled286 locationsNCT06925737
Recruiting
Phase 1

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Castration-Resistant Prostate Cancer (CRPC)ER+, HER 2- Breast Cancer+1 more
IDEAYA Biosciences160 enrolled11 locationsNCT07540572
Recruiting
Phase 3

Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance

Prostate Cancer
University of Texas Southwestern Medical Center291 enrolled1 locationNCT03769766